A randomized, open-label, dose finding study of the effect of subcutaneous administration of PEGASYS [peginterferon alfa-2a] on tumor response in patients with metastatic malignant melanoma
Latest Information Update: 03 Jun 2010
At a glance
- Drugs Peginterferon alfa-2a (Primary)
- Indications Malignant melanoma
- Focus Therapeutic Use
- Sponsors Roche
- 08 Jun 2006 New trial record.